by The global Leishmaniasis Treatment Market is estimated to be valued at US$ 69.4 Mn in 2023 and is expected to exhibit a CAGR of 17% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Leishmaniasis is a vector-borne disease caused by protozoan parasites of the genus Leishmania. It is transmitted by the bite of infected female phlebotomine sandflies. The disease manifests in three main forms: cutaneous, mucocutaneous, and visceral leishmaniasis. Symptoms vary depending on the form but may include skin sores, mucosal lesions, fever, weight loss, swelling of the spleen and liver. Treatment involves drugs such as pentavalent antimonials, miltefosine, paromomycin, and amphotericin B. Effective treatment is required to reduce disease burden and prevent fatalities as leishmaniasis can be fatal if left untreated.
Market key trends:
The key driver for the leishmaniasis treatment market is the growing disease incidence worldwide, especially in developing nations. As per WHO estimates, 1.3 million new cases emerge annually. Warmer climate conditions due to global warming are enabling the spread of sandfly vectors to new geographic areas, contributing to disease transmission. Furthermore, rising international travel and population displacement due to conflicts are facilitating the movement of infections between endemic and non-endemic regions. Additionally, lack of effective vaccines against leishmaniasis pushes reliance on drug treatments. However, increasing parasitic resistance to first-line medicines amphotericin B and miltefosine poses a challenge. This is fueling research and development of novel drug candidates with different mechanisms of action and improved safety profiles. Development of new combination therapies can boost treatment efficacy and help overcome drug resistance issues over the forecast period.
Porter’s Analysis
Threat of new entrants: The biopharmaceutical industry requires huge R&D investment and regulatory approvals which poses high entry barriers for new players.
Bargaining power of buyers: The presence of few existing treatment options increases the bargaining power of buyers.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of substitutes and complexity of drug development process.
Threat of new substitutes: Development of novel drugs and alternative treatment therapies can pose threat of substitution.
Competitive rivalry: The leishmaniasis treatment market witnesses high competition owing to presence of large players and patent expiries of existing drugs.
Key Takeaways
The Global Leishmaniasis Treatment Market Size is expected to witness high growth, exhibiting CAGR of 17% over the forecast period, due to increasing investment in R&D of leishmaniasis drugs.
Regional analysis: North America dominates the global leishmaniasis treatment market owing to high awareness, healthcare expenditure and presence of major market players. However, Asia Pacific is anticipated to exhibit fastest growth during the forecast period due to rising infection prevalence and improving healthcare infrastructure in developing countries.
Key players: Key players operating in the leishmaniasis treatment market include Merck, iCo Therapeutics, AEterna Zentaris, AEterna Zentaris AG, Eurofins Advinus, Pieris Pharmaceuticals, Dafra Pharma. Merck dominates the market with its pentavalent antimonial drug Sodium Stibogluconate (Pentostam).
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
